A Modern Vaccine (COVID-19) is seen at the LA Mission’s homeless shelter on Skid Row, Los Angeles, California, USA, February 10, 2021.
Lucy Nicholson | Reuters
Moderna said on Thursday that it expects to generate $ 18.4 billion in sales of the Covid-19 vaccine this year.
At the launch of its fourth-quarter earnings, Moderna also said that its chief physician, Tal Zaks, will leave the company at the end of September. The company said it retained Russell Reynolds “to recruit for a new CMO with global and commercial experience.”
Moderna shares increased by 3.9% in premarket trading.
The news comes a day after the company said it expects to produce at least 700 million doses of Covid vaccine this year. He also said he expects to produce up to 1.4 billion doses of Covid vaccine in 2022.
Pfizer, which also has a vaccine authorized for use in the United States, said earlier this month that it expects to sell in doses of about $ 15 billion this year.
Moderna has an agreement with the federal government for 300 million doses and has delivered about 55 million doses to the US It is expected to deliver the first 100 million doses to the US by the end of the first trimester, the second 100 million doses of towards the end of May and the third until August.
Modern, like other vaccine manufacturers, has worked quickly to meet the demand for gunfire that will hopefully help end the pandemic, which has infected more than 112 million people and killed at least 2.4 million, according to data compiled by Johns Hopkins University.
The company is in talks with the Food and Drug Administration over a proposal to fill its Covid vaccine vials with up to five additional doses to ease the blockage in manufacturing. One bottle of Modern Modern vaccine contains 10 doses, enough to inoculate five people, according to the Centers for Disease Control and Prevention.
The company also said on Thursday that it is in talks with the COVAX initiative, supported by the World Health Organization, to provide doses this year and in 2022.
The Moderna vaccine has been approved by the FDA for use in people 18 years of age and older. Studies in clinical trials are incomplete for children, whose immune systems may respond differently to adults.
The company said on Thursday that it had completed the enrollment of 3,000 participants in a clinical trial testing its vaccine in children aged 12 to 17.